Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(13%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
4
50%
Ph early_phase_1
1
13%
Ph phase_1
3
38%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 13 (37.5%)
Phase 24 (50.0%)

Trials by Status

withdrawn225%
active_not_recruiting113%
completed563%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_1

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

NCT05975021
completedphase_1

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

NCT02477449
completedphase_2

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

NCT04325035
completedphase_2

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

NCT02617446
completedearly_phase_1

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

NCT02772068
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05975021Phase 1

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Active Not Recruiting
NCT02477449Phase 1

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Completed
NCT04325035Phase 2

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Completed
NCT02617446Phase 2

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Completed
NCT02772068Early Phase 1

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

Completed
NCT00838253Phase 2

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

Withdrawn
NCT00869115Phase 1

Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure

Withdrawn
NCT00616161Phase 2

A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8